GFAP and Alzheimer disease: We aimed to implement these findings by evaluating a cohort of symptomatic patients diagnosed with sporadic AD, by exploring possible correlations between regional hypometabolism of 18F-FDG-PET and changes in CSF biomarkers of microglial and astrocytic reactivity (sTREM-2, GFAP and β-S100).